Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 5Phase 1 3Phase NA 2Phase 4 2Phase EARLY_PHASE1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2

Conditions

Breast Neoplasms 207Neoplasms 130Polycystic Ovary Syndrome 107Carcinoma, Hepatocellular 82Colorectal Neoplasms 77Prostatic Neoplasms 70Stomach Neoplasms 55Lung Neoplasms 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Carcinoma, Non-Small-Cell Lung 43Pancreatic Neoplasms 41Pain, Postoperative 41Head and Neck Neoplasms 38Pain 37Liver Neoplasms 36Leukemia, Myeloid, Acute 32Leiomyoma 32Keratosis, Actinic 31Colonic Neoplasms 31Recurrence 30Neoplasm Metastasis 29Multiple Myeloma 28Infertility 28Brain Neoplasms 28Uterine Cervical Neoplasms 26Urinary Bladder Neoplasms 24Ovarian Neoplasms 24Lymphoma 24Esophageal Neoplasms 23Obesity 22

Interventions

pasireotide 1lanreotide 1Somatostatin 1Octreotide 1Diazoxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × OTHER × Gastro-enteropancreatic neuroendocrine tumor × Clear all
NCT05701241 2024-06-14

SAUNA

University Hospital, Antwerp

Phase 4 Recruiting
270 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

University of Maryland, Baltimore

Phase 4 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡